Great Point Partners as of June 30, 2015
Portfolio Holdings for Great Point Partners
Great Point Partners holds 33 positions in its portfolio as reported in the June 2015 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Connecture | 17.0 | $44M | 4.1M | 10.56 | |
Adamas Pharmaceuticals | 7.9 | $20M | 773k | 26.22 | |
Vanda Pharmaceuticals (VNDA) | 7.0 | $18M | 1.4M | 12.69 | |
Five Prime Therapeutics | 6.6 | $17M | 679k | 24.84 | |
Synergy Pharmaceuticals | 6.5 | $17M | 2.0M | 8.30 | |
Dyax | 4.9 | $13M | 473k | 26.50 | |
Paratek Pharmaceuticals | 4.2 | $11M | 415k | 25.77 | |
Relypsa | 3.1 | $7.9M | 240k | 33.09 | |
Alcobra | 3.0 | $7.8M | 1.2M | 6.54 | |
Alimera Sciences | 3.0 | $7.8M | 1.7M | 4.61 | |
Sunesis Pharmaceuticals | 3.0 | $7.6M | 2.5M | 3.01 | |
Bovie Medical Corporation | 2.9 | $7.5M | 2.7M | 2.79 | |
Ocera Therapeutics | 2.9 | $7.5M | 2.0M | 3.80 | |
Vericel (VCEL) | 2.9 | $7.4M | 2.1M | 3.57 | |
Aradigm | 2.9 | $7.4M | 1.0M | 7.38 | |
Antares Pharma | 2.3 | $5.8M | 2.8M | 2.08 | |
Aurinia Pharmaceuticals (AUPH) | 2.3 | $5.8M | 1.9M | 2.99 | |
D Stemline Therapeutics | 2.2 | $5.6M | 475k | 11.77 | |
Ascendis Pharma A S (ASND) | 2.1 | $5.5M | 311k | 17.68 | |
Caladrius Biosciences | 1.8 | $4.6M | 2.5M | 1.87 | |
Zogenix | 1.6 | $4.2M | 2.5M | 1.68 | |
Biodel | 1.6 | $4.1M | 4.0M | 1.03 | |
Tenax Therapeutics | 1.6 | $4.1M | 1.1M | 3.69 | |
Sagent Pharmaceuticals | 1.3 | $3.4M | 142k | 24.31 | |
XenoPort | 1.2 | $3.0M | 485k | 6.13 | |
Exelixis (EXEL) | 1.1 | $2.8M | 745k | 3.76 | |
Orexigen Therapeutics | 0.8 | $2.2M | 440k | 4.95 | |
Derma Sciences | 0.8 | $2.0M | 280k | 7.16 | |
Enanta Pharmaceuticals (ENTA) | 0.6 | $1.6M | 35k | 45.00 | |
Athersys | 0.4 | $1.1M | 908k | 1.21 | |
Esperion Therapeutics (ESPR) | 0.3 | $687k | 8.4k | 81.79 | |
Streamline Health Solutions (STRM) | 0.2 | $425k | 152k | 2.80 | |
BioDelivery Sciences International | 0.0 | $82k | 10k | 7.96 |